FindMyKOL
Clinical trialNCT02353390CompletedInterventional

Oral Water Hydration to Prevent Post-Vaccination Presyncope

NCT02353390 is an interventional trial sponsored by Duke University. As of 21 Nov 2026, it is completed. It studies Presyncope and Syncope. The registry lists an enrollment of 1,820 participants at 2 sites in 1 country. The registry lists a start date of 31 Mar 2015 and a primary completion date of 30 Jun 2016.

SponsorDuke University →Enrollment1,820PresyncopeSyncope
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02353390
FieldValue
Registry IDNCT02353390
StatusCompleted
Study typeInterventional trial
Lead sponsorDuke University
Enrollment1,820
Registered sites2
Countries1
ConditionsPresyncope and Syncope
Start31 Mar 2015
Primary completion30 Jun 2016
Study completion30 Jun 2016
Last update posted7 Jul 2016

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a randomized controlled open-label trial. During the study, adolescents and young adults scheduled to receive at least one intra-muscular (IM) vaccine will receive either oral water hydration in addition to standard care or standard of care alone to evaluate the effect of water hydration on the primary outcome of presyncope. This study will also evaluate the acceptability of pre-vaccination hydration among adolescents and young adults.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Massachusetts, United States1 site
  • Boston Medical Center

    Boston

North Carolina, United States1 site
  • Duke University Medical Center

    Durham

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusetts: 1 siteMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth Carolina: 1 siteNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT02353390

Each answer restates registry values shown on this page.

What is NCT02353390?

NCT02353390 is an interventional trial sponsored by Duke University. It studies Presyncope and Syncope.

Who leads NCT02353390?

The registry names Alex R Kemper, MD, MPH, MS (principal investigator, Duke University), Elizabeth D Barnett, MD (principal investigator, Boston University), and Theresa Harrington, MD (principal investigator, Centers for Disease Control and Prevention) as overall officials.

Where does NCT02353390 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

When did NCT02353390 end?

The registry lists a primary completion date of 30 Jun 2016 and a study completion date of 30 Jun 2016. The sponsor last updated the record on 7 Jul 2016.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.